Rwanda has launched Africa’s first Phase 1b clinical trial of a potential long-acting injectable (LAI) designed to prevent malaria, marking a significant milestone in the development of new malaria prevention tools.
Medicines for Malaria Venture (MMV) and Rinda Ubuzima, a leading Rwandan health research organisation, announced the commencement of the trial, which will evaluate a promising compound known as MMV371.
The development could pave the way for a new approach to malaria prevention, as long-acting injectables have the potential to provide extended protection through a single administration, complementing existing interventions such as vector control, vaccines and preventive medicines.
The Need for New Malaria Prevention Tools
Despite significant progress in malaria control since the beginning of the century, the disease remains a major public health challenge, particularly in Africa.
According to the World Health Organization (WHO), malaria caused more than 280 million cases and over 600,000 deaths worldwide in 2024, with approximately 95 per cent of the deaths occurring in Africa.
The continued emergence of antimalarial drug resistance, changing disease patterns linked to climate-related extreme weather events and fragile healthcare systems have further highlighted the need for sustained investment in research and development, as well as improved access to prevention and treatment.
In response to these challenges, MMV is working with partners to develop the first long-acting injectable designed to offer extended protection against malaria.
The Phase 1b trial builds on earlier clinical research conducted in the United Kingdom, where MMV371 was found to be well tolerated in healthy adults and demonstrated the potential to provide protection for approximately three months.
The latest study will assess the compound’s safety and tolerability among adults and adolescents in Rwanda, explore its efficacy and examine how the body absorbs and processes it.
Speaking on the development, Dr Martin Fitchet, Chief Executive Officer of MMV, said eliminating malaria would require both wider access to existing interventions and the development of new prevention technologies.
“To eliminate malaria, we will need not only wider access to today’s tools but also the next generation of prevention technologies,” he said.
“Long-acting injectables have the potential to redefine how malaria prevention is delivered, providing sustained protection from a single administration and expanding the options available to communities at risk.”
Partnerships Driving Malaria Research
Partnerships remain central to the development of new malaria interventions, with MMV maintaining collaborations across the pharmaceutical industry, government and academia to bring innovative medicines to affected communities.
Its collaboration with Rinda Ubuzima reflects a shared commitment to advancing locally led research, strengthening scientific capacity and generating the evidence needed to develop the next generation of malaria prevention tools.
Marie Michele Umulisa, Executive Director of Rinda Ubuzima, said conducting the study in Rwanda demonstrated the importance of partnerships in ensuring African researchers and institutions play active roles in developing solutions for their communities.
“We are proud to contribute to research that could help shape the future of malaria prevention while strengthening locally led scientific innovation,” she said.
As countries intensify efforts to eliminate malaria, the clinical trial represents another step towards expanding the range of preventive options available to at-risk populations.
It also highlights the growing role of malaria-endemic African countries in conducting advanced early-stage clinical research, ensuring that local researchers and institutions contribute to the development of medicines intended for their communities
4,000 receive free medical care as foundation feeds 10,000 in Ogbomoso
By Ogochukwu Agha No fewer than 4,000 residents of Ogbomosoland received medical care during a five-day outreach organised by the Funmi Adewole Foundation in collaboration with the healthcare and medical committee of the...

No comments yet. Start the conversation.